Gemini Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Boston MA United States (2015)
Status: Acquired by Disc Medicine, Inc (2022)

Organization Overview

First Clinical Trial
2019
NCT04246866
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Gemini Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

aflibercept (zaltrap) (1 trial)

gem103 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Geographic Atrophy (Phase 2)

Macular Degeneration (Phase 2)

Retinal Degeneration (Phase 2)

Retinal Diseases (Phase 2)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2